Table 1.
Comparison | Cell Line | Groups | Treatment | Time Point | Sample Number |
---|---|---|---|---|---|
1 |
BT474 |
Group 1 |
1 μM lapatinib |
6 hr & 12 hr |
8 |
Group 2 |
0.1 μM lapatinib |
2 hr & 6 hr & 12 hr & 24 hr |
16 |
||
1 μM lapatinib |
2 hr |
4 |
|||
0.1% DMSO |
0 hr & 2 hr & 6 hr & 12 hr & 24 hr |
20 |
|||
Total |
|
|
48 |
||
2 |
BT474 |
Group 1 |
1 μM lapatinib |
6 hr & 12 hr |
8 |
Group 2 |
0.1 μM lapatinib |
6 hr & 12 hr |
8 |
||
Total |
|
|
16 |
||
3 |
SKBR3 |
Group 1 |
1 μM lapatinib |
6 hr & 12 hr |
8 |
0.1 μM lapatinib |
6 hr & 12 hr |
8 |
|||
Group 2 |
0.1 μM lapatinib |
2 hr & 24 hr |
8 |
||
1 μM lapatinib |
2 hr |
4 |
|||
0.1% DMSO |
0 hr & 2 hr & 6 hr & 12 hr & 24 hr |
20 |
|||
Total |
|
|
48 |
||
4 |
SKBR3 |
Group 1 |
1 μM lapatinib |
6 hr & 12 hr |
8 |
0.1 μM lapatinib |
6 hr & 12 hr |
8 |
|||
Group 2 |
0.1 μM lapatinib |
2 hr |
4 |
||
1 μM lapatinib |
2 hr |
4 |
|||
0.1% DMSO |
0 hr & 2 hr & 6 hr & 12 hr & 24 hr |
20 |
|||
Total |
|
|
44 |
||
5 |
SKBR3 |
Group 1 |
1 μM lapatinib |
12 hr |
4 |
0.1 μM lapatinib |
12 hr |
4 |
|||
Group 2 |
0.1 μM lapatinib |
2 hr & 6 hr & 24 hr |
12 |
||
|
1 μM lapatinib |
2 hr & 6 hr |
8 |
||
|
0.1% DMSO |
0 hr & 2 hr & 6 hr & 12 hr & 24 hr |
20 |
||
Total |
|
|
48 |
||
6 |
SKBR3 |
Group 1 |
1 μM lapatinib |
12 hr |
4 |
|
|
0.1 μM lapatinib |
12 hr |
4 |
|
|
|
Group 2 |
0.1 μM lapatinib |
2 hr & 6 hr |
8 |
|
|
|
1 μM lapatinib |
2 hr & 6 hr |
8 |
|
|
|
0.1% DMSO |
0 hr & 2 hr & 6 hr & 12 hr & 24 hr |
20 |
Total | 44 |